Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2013

View Archived Issues

Minocycline may sensitize recurrent glioblastoma after bevacizumab failure

Buparlisib generally well tolerated in glioblastoma multiforme trial

Covagen secures series B financing to advance COVA-322

New phase II study to investigate MOR-208 with lenalidomide in CLL

Novel endochin-like quinolones as cytochrome bc1 inhibitors for Plasmodium infection

Soligenix begins phase II trial of SGX-942 for the treatment of oral mucositis

Astellas Pharma and Vical begin phase II trial of ASP-0113 CMV vaccine

EPOCH study of MK-8931 in Alzheimer's disease to continue after interim safety analysis

Incozen Therapeutics presents BIA-6 as a novel antitumor agent

Enanta Pharmaceuticals and AbbVie report data from phase III trial SAPPHIRE-II

Lundbeck and Otsuka set to codevelop Alzheimer's disease vaccine

NewLink Genetics begins phase I trial of NLG-919

Treatment phase of MGN-1703 safety trial completed

Verastem begins phase I trial of VS-5584 in solid tumors and lymphomas

Juventus studies retrograde infusion of gene therapy in patients with symptomatic heart failure

Dual BCR-ABL and MNK kinase inhibitors developed for blast crisis chronic myeloid leukemia

GlaxoSmithKline presents new tankyrase inhibitors for cancer

French researchers disclose novel mGlu2 receptor modulators

GlaxoSmithKline patents novel TYK2 inhibitors

Orion Corp. synthesizes new series of COMT inhibitors

IDE application submitted to the FDA for Gencaro companion diagnostic

Scientists at Convergence Pharmaceuticals synthesize new Na(v)1.7 blockers

Novel pim kinase inhibitors reported by Novartis for cancer and other disorders

KNG-I-484C described as novel candidate for NSCLC

FDA grants priority review to Cerdelga for Gaucher's disease

Synthetic Biologics investigates new approaches for IBS

Orexigen Therapeutics resubmits NDA for Contrave

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...